Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_4
1
17%
Ph phase_3
1
17%
Ph phase_2
3
50%
Ph phase_1
1
17%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(2)
Terminated(3)
Other(1)

Detailed Status

Completed2
Terminated2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 31 (16.7%)
Phase 41 (16.7%)

Trials by Status

completed233%
terminated233%
unknown117%
withdrawn117%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_1

Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

NCT02423954
withdrawnphase_2

Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers

NCT02720601
completedphase_2

Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer

NCT01322152
unknownphase_3

Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer

NCT01501669
completedphase_4

Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours

NCT00220168
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02423954Phase 1

Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Terminated
NCT02720601Phase 2

Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers

Withdrawn
NCT01322152Phase 2

Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer

Completed
NCT01501669Phase 3

Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer

Unknown
NCT00220168Phase 4

Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours

Completed
NCT00506168Phase 2

Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6